drugset / Trial / NCT00095173

BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

NCT00095173

Phase 3 Completed 214 enrolled Bristol-Myers Squibb
RandomizedSingle-groupDouble-blindTreatment

Summary

The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare.

Timeline

Start
2003-12
Primary completion
2006-06
Completion
2011-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 10 mg/kg Intravenous